Immunotherapy News and Research

Latest Immunotherapy News and Research

Microbial signals rewire immunity in esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia.

21 Jul 2025

Cuproptosis offers new hope for treating inflammatory bowel disease and colorectal cancer

Cuproptosis represents a novel mechanism of cell death characterized by intracellular copper ion accumulation.

18 Jul 2025

New mRNA vaccine strategy awakens immune system to fight cancer

An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

18 Jul 2025

New monoclonal antibody enhances immune response by selectively targeting Tregs

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment."

17 Jul 2025

Prestigious Stephenson Scholar Grants support cutting-edge pancreatic cancer studies

The Stephenson Global Pancreatic Cancer Research Institute and its partner City of Hope, one of the country's largest and most advanced cancer research and treatment organizations, today announced the six inaugural recipients of the prestigious Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection and treatment of pancreatic cancer.

16 Jul 2025

Fred Hutch leads national study on multi-cancer detection blood tests

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests.

16 Jul 2025

Research unravels the immune secrets of a cured pediatric rhabdoid tumor

Although relatively rare, many childhood cancers remain life-threatening and lack effective personalized treatments. Rhabdoid tumors are among these fatal cancers and can develop in various tissues and organs.

16 Jul 2025

WEE1 identified as a key driver of immune resistance in cancer

Immune checkpoints are regulatory proteins that prevent the immune system from attacking healthy tissues.

15 Jul 2025

Nasal antibody spray shields mice from pollen-triggered allergies and asthma

Intranasal delivery of a monoclonal IgG1 antibody targeting mugwort pollen protected mice from allergic rhinitis and asthma symptoms, without lowering systemic IgE levels. This localized, non-invasive approach dampened Th2 inflammation and preserved healthy airway tissue in sensitized mice.

14 Jul 2025

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

14 Jul 2025

New immunotherapy targets leukemia at its root

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells – and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival.

14 Jul 2025

Long-term survival achieved in stage III melanoma with pre-surgery immunotherapy

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

12 Jul 2025

Pathogenic mechanisms of Fusobacterium nucleatum in colorectal cancer and emerging therapies

In recent years, the regulatory role of the gut microbiota in the initiation and progression of colorectal cancer (CRC) has attracted growing attention. Among the key microbial contributors, Fusobacterium nucleatum (Fn) has been identified as a critical pathogenic factor in CRC.

12 Jul 2025

High-intensity focused ultrasound induces ferroptosis for tumor immune activation

This new article publication from Acta Pharmaceutica Sinica B, discusses high intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming.

12 Jul 2025

Engineered exosomal spheres enhance melanoma immunotherapy through improved tumor penetration

This new article publication from Acta Pharmaceutica Sinica B, discusses the use of engineered platelet-derived exosomal spheres for enhanced tumor penetration and extended circulation in melanoma immunotherapy.

12 Jul 2025

Teclistamab shows promising results in heavily pretreated multiple myeloma

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes.

12 Jul 2025

Monoclonal antibody delivered through the nose blocks hay fever in mice

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 million school- and workdays every year.

11 Jul 2025

Hydrogels could be key to safer, smarter cancer drug delivery

Hydrogels could revolutionize cancer treatment by facilitating targeted drug delivery, reducing adverse effects, and enhancing therapeutic effectiveness.

11 Jul 2025

How hydrogels are shaping the future of targeted cancer drug delivery

A large-scale bibliometric analysis maps global research on hydrogels as next-generation drug delivery systems for cancer therapy. The study highlights emerging trends, key contributors, and future directions to advance precision medicine in oncology.

10 Jul 2025

Updated NeoVax cancer vaccine shows improved immune response in melanoma trial

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.

10 Jul 2025